• last year
(Adnkronos) - “Come Gruppo Menarini siamo orgogliosi di aver intrapreso questo percorso di impegno nella ricerca e nello sviluppo di farmaci in ambito oncoematologico. Oggi siamo qui per condividere la recente approvazione da parte dell’Agenzia italiana del farmaco di una nuova molecola first in class per il trattamento del mieloma multiplo: selinexor”. Così Nicola Bencini, general manager di Menarini Stemline Italia, in occasione della conferenza stampa con la quale l’azienda farmaceutica ha annunciato il via libera di Aifa alla rimborsabilità di selinexor, inibitore orale selettivo della proteina XPO1, in associazione a bortezomib e desametasone per il trattamento di pazienti adulti con mieloma multiplo sottoposti ad almeno una terapia precedente. L’incontro è stato l’occasione per parlare anche di un’altra opzione terapeutica, la prima terapia specifica per la neoplasia a cellule dendritiche plasmacitoidi blastiche: tagraxofusp.

Category

🗞
News
Transcript
00:00As the Minarini Group, we are proud to have undertaken, a few years ago, this path of commitment to research and the development of drugs in the hematological field.
00:15Today we are here to share the recent approval of the Agency of Pharmacy for a new molecule, a first-in-class, non-inhibitor of protein XPO1, Selnexor,
00:27which has received two indications, one in the early lines, with a triple association of Selnexor with Bortezomib and Dexamethasone,
00:38for the first-in-class patients, and one in the advanced lines, for patients with pentarefractories, in association with Solodexamethasone.
00:47This therapeutic innovation follows that of Tagraxopus, which is a target therapy inhibitor of CD123, which received approval last year for patients affected by PPD-CN,
00:59an orphan, but lethal pathology, and which requires a multidisciplinary approach for a correct diagnosis path,
01:11and Tagraxopus certainly represents an additional therapeutic innovation at the disposal of patients in an attempt to be resuscitated to a transplant condition.
01:23All this has been made possible thanks to a close collaboration with the Excellence of Italian Hematology, with the Academy, the University,
01:35and the next steps will certainly go in this direction, trying to bring as much innovation as possible for patients affected by blood tumors.

Recommended